BioAtla, Inc. SEC filings BCAB
BioAtla, Inc. has 509 filings in SEC EDGAR's recent list, going back to Oct 6, 2020. Its latest annual report, Form ARS, was filed on Jun 3, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 20, 2026 (material agreement, agreement ended, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jun 3, 2026 | — |
| DEF 14A | Proxy statement | Jun 3, 2026 | Jun 3, 2026 |
| DEFA14A | Additional proxy material | Mar 2, 2026 | — |
| DEFM14A | Filing | Feb 11, 2026 | — |
| PREM14A | Filing | Jan 30, 2026 | Jan 30, 2026 |
| DEFA14A | Additional proxy material | Jan 15, 2026 | — |
| DEFA14A | Additional proxy material | Dec 31, 2025 | — |
| DEF 14A | Proxy statement | Dec 5, 2025 | Dec 5, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 24, 2025 | Nov 24, 2025 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Apr 24, 2025 |
| DEFA14A | Additional proxy material | Apr 24, 2024 | — |
| DEF 14A | Proxy statement | Apr 24, 2024 | Jun 13, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2023 | — |
| DEF 14A | Proxy statement | Apr 24, 2023 | Jun 14, 2023 |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 16, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 15, 2021 |
Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCAB (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1826892
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.